After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Like most drugs, Ebglyss may cause mild to serious side effects ... you’re encouraged to call Eli Lilly and Company (the drugmaker) at 800-LillyRx (800-545-5979) to share your experience ...
New data shows Ebglyss achieved deep and sustained response ... Also Read: Alzheimer’s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding Additionally, 87% achieved or ...
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis (AD) in a Phase III trial. The US ...
Drugs for metabolic diseases ... is tipped for sales of $1.6 billion. 4) Eli Lilly and Almirall's Ebglyss (lebrikizumab), an anti-IL-13 antibody for atopic dermatitis that offers less frequent ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback